Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2529611 | 0.90 | MT-CO2 (0.42) | L3MBTL1RAB9AGSK3BBCHEBRD4 | |
| SCHEMBL5604575 | 0.90 | PAX8 (0.43) | KMT2ACYP2C9SMN1; SMN2BRD4PAX8 | |
| SCHEMBL12140384 | 0.87 | BRD4 (0.40) | L3MBTL1NPSR1KMT2AMEN1CYP3A4 | |
| SCHEMBL1706045 | 0.87 | FFAR1 (0.41) | NPSR1SMN1; SMN2RAB9APAX8MAPT | |
| SCHEMBL504005 | 0.85 | L3MBTL1 (0.55) | L3MBTL1TDP1ATMNPSR1KMT2A | |
| SCHEMBL5766183 | 0.84 | MAPT (0.42) | KMT2AMEN1SMN1; SMN2PAX8ALDH1A1 | |
| SCHEMBL977449 | 0.84 | ALDH1A1 (0.42) | TDP1NPSR1KMT2AMEN1CYP3A4 | |
| SCHEMBL3410365 | 0.84 | MT-CO2 (0.39) | TDP1KMT2ASMN1; SMN2RAB9APAX8 | |
| SCHEMBL15948302 | 0.82 | F2 (0.38) | KMT2AGSK3BPAX8CHRM5MAPT | |
| SCHEMBL273986 | 0.82 | MEN1 (0.39) | KMT2AMEN1SMN1; SMN2RAB9APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111699250-B | Carboxylesterase polypeptides for amide coupling | 科德克希思公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-116685583-A | Pyrimidine compounds, compositions and pharmaceutical uses thereof | 缆图药品公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-113683629-B | Substituted heteroaryl compounds, compositions and uses thereof | 北京范恩柯尔生物科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-115991884-A | Resin microsphere with covalent bonding heavy metal ion probe and application thereof | 华中师范大学 | 2023-04-21 | — | — | CN | disclosed |
| CN-114195676-B | Biarylhydrazine compound and adduct thereof and application of compound in preparation of antitumor drugs | 广州药本君安医药科技股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114195676-A | Biarylhydrazine compound and adduct thereof and application of compound in preparation of antitumor drugs | 广州药本君安医药科技股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-113683629-A | Substituted heteroaryl compounds, compositions and uses thereof | 北京范恩柯尔生物科技有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-108137505-B | Nitrogen-containing heterocyclic compound | 富士胶片株式会社 | 2021-07-06 | — | — | CN | disclosed |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | FUJIFILM CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| EP-3563851-B1 | ANTITUMOR AGENT AND BROMODOMAIN INHIBITOR | FUJIFILM CORP (JP) | 2021-04-21 | — | — | EP | disclosed |
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241773-B2 | 3-quinuclidinyl heteroatom bridged biaryl derivatives | ABBOTT LABORATORIES (US) | 2007-07-10 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| CN-1854128-A | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-11-01 | — | — | CN | disclosed |
| CN-1266112-C | Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-07-26 | — | — | CN | disclosed |
| US-20060058298-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2006-03-16 | — | — | US | disclosed |
| EP-1429765-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | L3MBTL1 1627/4885TDP1 1232/4885ATM 1158/4885 |
| US-10987349-B2 | Antitumor agent and bromodomain inhibitor | BRD4, BRD1, BRD3 | L3MBTL1 209/4885TDP1 2957/4885ATM 3490/4885 |
| US-20060058298-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | L3MBTL1 1291/4885TDP1 926/4885ATM 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.